Arrowhead Pharmaceuticals is a clinical stage company listed on Nasdaq under the ticker ARWR, engaged in the development of innovative medicines targeting intractable diseases through gene silencing. Leveraging a comprehensive portfolio of RNA chemistries and efficient delivery methods, Arrowhead's therapeutics activate the RNA interference mechanism, resulting in rapid and sustained reduction of specific gene expression. This cutting-edge approach positions their RNAi-based therapies at the forefront of genetic-based treatment, offering the potential for transformative solutions for patients facing challenging medical conditions. Research and development activities are conducted in Madison, WI, while their headquarters, along with clinical and regulatory operations, are based in Pasadena, CA.

Services include:
- Targeted RNAi Molecules (TRiM) platform
- RNA interference therapeutics
- Ligand-mediated delivery systems
- Simplified drug manufacturing processes
- Multiple routes of administration
- Safety assessment and toxicology

Through their robust capabilities in chemistry, biology, and toxicology, Arrowhead Pharmaceuticals aims to rapidly discover and develop effective RNAi-based therapeutics to expand their pipeline. For more information, please visit arrowheadpharma.com.